Cargando…

Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery

Coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a global health emergency and no clinically approved vaccines or antiviral drugs available to date. Intensive research on SARS-CoV-2 is urgently warranted to understand its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chellapandi, P., Saranya, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394272/ https://www.ncbi.nlm.nih.gov/pubmed/32837137 http://dx.doi.org/10.1007/s00044-020-02610-8

Ejemplares similares

A hijack mechanism of Indian SARS-CoV-2 isolates for relapsing contemporary antiviral therapeutics
por: Prathiviraj, R., et al.
Publicado: (2021)

Drug discovery targeting SARS-CoV-2 membrane fusion
por: Yang, Kailu, et al.
Publicado: (2023)

Drug discovery and development targeting the life cycle of SARS-CoV-2
por: Su, Haixia, et al.
Publicado: (2021)

Drug Discovery Strategies for SARS-CoV-2
por: Shyr, Zeenat A., et al.
Publicado: (2020)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase
por: White, Mark Andrew, et al.
Publicado: (2020)

Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
por: Amin, Sk Abdul, et al.
Publicado: (2021)

Identification of genotypic variants and its proteomic mutations of Brazilian SARS-CoV-2 isolates
por: Prathiviraj, Ragothaman, et al.
Publicado: (2022)

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
por: Wu, Canrong, et al.
Publicado: (2020)

Production of Proteins of the SARS-CoV-2 Proteome for Drug Discovery
por: Kim, Choon, et al.
Publicado: (2021)

miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery
por: Alam, Tanvir, et al.
Publicado: (2021)

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery
por: Mulay, A., et al.
Publicado: (2020)

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery
por: Mulay, Apoorva, et al.
Publicado: (2021)

Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2022)

SARS-CoV-2 Nucleocapsid Protein Is a Potential Therapeutic Target for Anticoronavirus Drug Discovery
por: Royster, Austin, et al.
Publicado: (2023)

Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential
por: Mullen, Tracey E, et al.
Publicado: (2021)

Potential drug targets of SARS-CoV-2: From genomics to therapeutics
por: Shamsi, Anas, et al.
Publicado: (2021)

Déjà vu: Stimulating open drug discovery for SARS-CoV-2
por: Ekins, Sean, et al.
Publicado: (2020)

SARS‐CoV‐2–host proteome interactions for antiviral drug discovery
por: Liu, Xiaonan, et al.
Publicado: (2021)

Targeted Hybridization Capture of SARS-CoV-2 and Metagenomics Enables Genetic Variant Discovery and Nasal Microbiome Insights
por: Nagy-Szakal, Dorottya, et al.
Publicado: (2021)

Decoding Covid-19 with the SARS-CoV-2 Genome
por: Ellis, Phoebe, et al.
Publicado: (2021)

Promising inhibitors targeting M(pro): an ideal strategy for anti-SARS-CoV-2 drug discovery
por: Chen, Yi, et al.
Publicado: (2020)

COVID-19 prediction based on genome similarity of human SARS-CoV-2 and bat SARS-CoV-like coronavirus
por: Arslan, Hilal
Publicado: (2021)

The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects
por: Al-Salihi, Karima A., et al.
Publicado: (2021)

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
por: Bobrowski, Tesia, et al.
Publicado: (2020)

Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning
por: Riva, Laura, et al.
Publicado: (2020)

Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2
por: Ray, Manisha, et al.
Publicado: (2020)

Candidate drugs against SARS-CoV-2 and COVID-19
por: McKee, Dwight L., et al.
Publicado: (2020)

Drug repurposing for SARS-CoV-2 (COVID-19) treatment
por: Mtewa, Andrew G., et al.
Publicado: (2022)

Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets
por: Arooj, Mahreen, et al.
Publicado: (2021)

Insights from Zimbabwe's SARS-CoV-2 genomic surveillance
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2021)

SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics
por: Gupta, Ruchir, et al.
Publicado: (2020)

Insights into SARS‐CoV‐2 in Angola during the COVID‐19 peak: Molecular epidemiology and genome surveillance
por: Francisco, Ngiambudulu M., et al.
Publicado: (2023)

Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
por: Pozzi, Cecilia, et al.
Publicado: (2023)

Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection
por: Khare, Prashant, et al.
Publicado: (2020)

The discovery of antivirals and novel targets for SARS-CoV-2 and EV-A71
por: Haddad, Christina, et al.
Publicado: (2022)

SARS-CoV-2: from its discovery to genome structure, transcription, and replication
por: Brant, Ayslan Castro, et al.
Publicado: (2021)

Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19
por: van de Leemput, Joyce, et al.
Publicado: (2021)

A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing
por: Habibi, Mahnaz, et al.
Publicado: (2021)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tm7vjdbb2james8lu3bbr94b9l